Navigation Links
Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President
Date:8/22/2011

CHADDS FORD, Pa., Aug. 22, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Kelly Huang, Ph.D., to the position of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, an Endo subsidiary, is a leading U.S. provider of urological products and services based in Austin, Texas.

Huang will take over leadership from current HealthTronics Group President James Whittenburg, who is staying through the remainder of the year to effect a seamless transition as HealthTronics continues to provide exceptional urological products and services in improving patient care. Whittenburg joined HealthTronics in 2004, was appointed President and CEO in 2007 and became an Endo Group President in July 2010 with the acquisition of HealthTronics, Inc.

Prior to joining HealthTronics, Dr. Huang held the role of Vice President of Research & Development at Neutrogena, where he was also a member of the global Management Board.  Prior to Neutrogena, Dr. Huang established and headed the Molsaic Internal Venture, a startup sponsored by Johnson & Johnson's Development Corporation. Prior to Molsaic, Dr. Huang held leadership positions within Johnson & Johnson's Consumer business, which included spending two years in Paris, France, that drove innovation globally.

"I am very pleased to announce Kelly's appointment to lead our important HealthTronics subsidiary," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "Kelly brings a wealth of experience leading global businesses through the integration of scientific, consumer and professional insights and creating value by putting the customer and patient at the center. Kelly's experiences and skills will be invaluable to Endo's continued transformation to provide integrated healthcare solutions to patients, payers and providers, as well as HealthTronics' mission to provide the most advanced technology and premier support systems to urologists, hospitals, surgery centers and clinics. I would also like to thank James Whittenburg for his contributions to Endo.  Under his leadership, the HealthTronics business has become an industry leader and national provider of urological services and products."

About HealthTronics

HealthTronics, Inc. is a premier urology company providing an exclusive suite of healthcare services and technology, including urologist partnership opportunities, surgical and capital equipment, maintenance services and anatomical pathology services. The company's product portfolio includes a full line of urology equipment and products, including lithotripters, surgical lasers for treatment of BPH, and anatomical pathology services.  As a service provider, HealthTronics offers the latest technology in lithotripsy services and prostate therapy services, including BPH treatments and prostate cancer treatments.  For more information, visit www.healthtronics.com.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services.  We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
4. Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
6. Access Pharmaceuticals Provides Second Quarter Update on MuGard Commercial Activities
7. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
8. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
9. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
10. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... International plc (NASDAQ: ENDP ) (TSX: ENL) today ... president of Allergan, Inc. and current CEO of Chase Pharmaceuticals ... TPG Capital, to its Board of Directors. The appointments are ... recently embarked on a search for new Board members who ... and Todd are experienced leaders, and we are extremely pleased ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... The Price Agency in Birmingham, AL ... assist the people of their local community. The agency pledges to select a ... Their desire is to bring awareness to important local causes with fundraising and ...
(Date:5/6/2016)... ... May 06, 2016 , ... The joy associated with Mother’s Day is mixed with ... neonatal intensive care units (NICUs) across the country. For the first time ever, the ... honor these women who spend their Mother’s Day beside a crib surrounded by lifesaving equipment ...
(Date:5/6/2016)... ... ... US Sports Camps has collaborated with State Rugby Organization (SRO), Rugby Oregon, ... Employing world-class rugby figures, including former Team USA players and college coaches, this program ... match play, fitness and more. , “US Sports Camps is honored to be working ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ... offering for global clients of Coupa ( Coupa Software ) and other Cloud ... is a key component in the suite of innovative implementation services offered by ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
Breaking Medicine News(10 mins):